Use search to browse all 100+ peptides
GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate
A synthetic 29-amino acid analog of growth hormone-releasing hormone that stimulates pituitary gland to release growth hormone.
Sigdel. Madan M; Fakir. Saikat S; Sarker. Md Matiur Rahman MMR; Barabutis. Nektarios N
A lab study found that a peptide that blocks growth‑hormone‑releasing hormone (GHRH) can trigger the cell‑clean‑up process called autophagy in certain cancer cells that have GHRH receptors, but it does nothing in cells without those receptors.
Barabutis. Nektarios N; Schally. Andrew V AV
The study looked at a synthetic blocker of growth‑hormone‑releasing hormone (GHRH) called JMR‑132 in prostate cancer cells. It found that blocking GHRH reduced the cells' production of reactive oxygen species (ROS) and lowered markers of oxidative stress, acting like an antioxidant. However, this research used a GHRH antagonist, not sermorelin (a GHRH agonist), and was done in a lab cancer model, not in healthy people.
Kiaris. H H; Schally. A V AV
A study found that a drug that blocks growth‑hormone‑releasing hormone (GH‑RH) can lower the activity of telomerase, an enzyme tumors need to keep growing, in brain‑cancer cells in mice and in cell cultures. This effect seems to come from turning down a gene called hTRT that makes part of telomerase, not from changes in other related genes.
Jungwirth. A A; Schally. A V AV; Pinski. J J; Groot. K K; Armatis. P P; Halmos. G G
A study in mice showed that a drug blocking growth‑hormone‑releasing hormone (GH‑RH) called MZ‑4‑71 dramatically shrank kidney cancer tumors by cutting the body’s GH and IGF levels. The compound isn’t available to the public and the research isn’t about sermorelin, so there’s no direct protocol you can use.
Catanuto. Paola P; Tashiro. Jun J; Rick. Ferenc G FG; Sanchez. Patricia P; Solorzano. Carmen C CC; G...
Researchers found that thyroid cells, both normal and cancerous, have receptors for a hormone that normally tells the pituitary to release growth hormone. When they blocked this hormone’s signal with a drug called MIA‑602, the cancer cells showed less activity of an enzyme (MMP‑2) that helps tumors spread, but the drug didn’t change how fast the cells grew. Normal thyroid cells weren’t affected.
Perez. Roberto R; Schally. Andrew V AV; Vidaurre. Irving I; Rincon. Ricardo R; Block. Norman L NL; R...
In mice with human triple‑negative breast cancer tumors, a drug that blocks the hormone GHRH (called MIA‑602) slowed tumor growth and lowered levels of several inflammation‑related genes. The effect depended on the cancer cells having GHRH receptors, and turning off those receptors also reduced inflammatory signals.
Hümmelink. R R; Sippell. W G WG; Benoit. K G KG; Danielson. K K; Faijerson. Y Y
A small study gave kids with growth hormone deficiency a nasal spray of a hormone that normally tells the body to make growth hormone. It caused short bursts of hormone at first, but the effect faded, antibodies formed, and kids got nose irritation. Overall, it didn’t help them grow taller over six months.
Jungwirth. A A; Schally. A V AV; Pinski. J J; Halmos. G G; Groot. K K; Armatis. P P; Vadillo-Buenfil...
In mice and rats with aggressive prostate cancers, a drug that blocks the hormone that normally makes the body release growth hormone (called a GH‑RH antagonist) shrank the tumors and lowered levels of growth‑related proteins. The study was done only in animals and used a compound that isn’t sold as a supplement.
Stangelberger. Anton A; Schally. Andrew V AV; Varga. Jozsef L JL; Hammann. Brian D BD; Groot. Kate K...
In mice with prostate cancer, drugs that block the hormone that normally tells the body to release growth hormone (GHRH) and a related peptide (BN/GRP) slowed tumor growth and lowered levels of several growth‑promoting proteins. The study does not involve sermorelin, which is a GHRH‑activating peptide, so it offers little direct guidance for people using sermorelin for health or longevity.
Kovacs. M M; Zarándi. M M; Halmos. G G; Groot. K K; Schally. A V AV
In rats, a new drug that blocks the hormone that normally tells the pituitary to release growth hormone (GH) slowed growth, lowered blood GH and IGF‑I levels, and reduced the number of GH receptors in the pituitary. The effect was seen after both short‑term high‑dose injections and two weeks of daily low‑dose injections.
Aguilar. E E; Pinilla. L L
In rats, the ability of the pituitary gland to release growth hormone after a GHRH (sermorelin) injection changes with the female reproductive cycle and with removal of the ovaries. The response is strongest during the diestrus phase and weakest during proestrus, and cutting out the ovaries later in life reduces the response more than doing it early. These findings hint that female hormones can influence how well GHRH works, but the study is in animals and doesn’t give direct guidance for people.
Looij. B J BJ; Roelfsema. F F; van der Heide. D D; Frölich. M M; Souverijn. J H JH; Nieuwenhuij...
The study shows that giving human calcitonin to people reduces their growth hormone (GH) spikes, especially when the body is trying to release GH after low blood sugar or after a GH‑releasing hormone signal. It also causes a brief, small rise in prolactin and thyroid‑stimulating hormone, but doesn’t change calcium or magnesium levels. In short, calcitonin seems to block GH release, but not by the usual pathways.
Lapierre. H H; Farmer. C C; Girard. C C; Brazeau. P P
This animal study found that older cows clear growth hormone faster and have lower baseline levels, while cutting feed a bit slows clearance but doesn’t raise hormone levels. The hormone’s release rate stayed the same regardless of age or diet. Because it’s done in dairy heifers, the direct take‑away for human biohackers is limited.
Butenandt. O O; Staudt. B B
In a small study of kids with growth‑hormone deficiency, a single injection of growth‑hormone‑releasing hormone (GHRH) briefly raised hormone levels, but giving it regularly didn’t help them grow. Switching to standard recombinant human growth hormone (rhGH) made all the kids grow faster. The researchers concluded GHRH isn’t useful for routine treatment of this condition.
Lapierre. H H; Pelletier. G G; Petitclerc. D D; Dubreuil. P P; Morisset. J J; Gaudreau. P P; Couture...
In a study on dairy cows, giving a daily injection of the growth‑hormone‑releasing peptide (similar to sermorelin) for 10 days boosted milk, fat, and protein output by about 14‑17% and raised blood growth‑hormone spikes, with no sign that the cows became tolerant during that period. The effect faded after the injections stopped, and the research was done only in cows, not people.
Robberecht. P P; Waelbroeck. M M; de Neef. P P; Camus. J C JC; Vandermeers. A A; Vandermeers-Piret....
This study shows that a venom peptide called helodermin can stick to the same receptors in rat liver that the body’s natural VIP hormone uses, and that this binding can trigger a cellular signal (cAMP). It’s a basic lab experiment, not a human trial, and doesn’t give any dosing or safety info for people.
Szepeshazi. K K; Schally. A V AV; Groot. K K; Armatis. P P; Hebert. F F; Halmos. G G
In animal studies, drugs that block the hormone that normally tells the pituitary to release growth hormone (GH‑RH antagonists) shrank pancreatic tumors and cut the amount of a growth‑promoting protein called IGF‑II inside the tumors, while leaving IGF‑I unchanged.
Kovács. M M; Schally. A V AV; Zarándi. M M; Groot. K K
The study tested new chemicals that block the hormone that normally makes the body release growth hormone. In rats, these blockers cut the hormone‑boosting effect by about two‑thirds and lasted for at least 15 minutes. One compound was especially strong, working many times better than older blockers, and could lower growth hormone levels when given by injection. The researchers think such blockers might someday help treat cancers that rely on growth‑factor signaling.
Plonowski. A A; Schally. A V AV; Varga. J L JL; Rekasi. Z Z; Hebert. F F; Halmos. G G; Groot. K K
In mice with prostate cancer, drugs that block the hormone that normally tells the body to release growth hormone (GHRH) slowed tumor growth, especially when combined with another drug that blocks bombesin/EGF signals. This study used GHRH antagonists, not the GHRH‑stimulating peptide sermorelin that many biohackers take.
Zhao. Lin L; Yano. Tetsu T; Osuga. Yutaka Y; Nakagawa. Shunsuke S; Oishi. Hajime H; Wada-Hiraike. Os...
A lab study showed that a molecule that blocks growth‑hormone‑releasing hormone (GHRH) can kill endometrial cancer cells in a dish by triggering cell‑death pathways, but this was done in isolated cells, not people, and uses a different compound than the commonly used peptide sermorelin.